Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Существуют ли перспективы применения петлевых диуретиков для лечения артериальной гипертензии? - Научно-практический журнал Cardioсоматика Том 2, №1 (2011)
Существуют ли перспективы применения петлевых диуретиков для лечения артериальной гипертензии?
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Обсуждаются показания к применению петлевых диуретиков для лечения артериальной гипертензии и ограничения, существующие в настоящее время с точки зрения их внедрения в практику рутинной антигипертензивной терапии. На примере торасемида продемонстрированы перспективы применения петлевых диуретиков для лечения артериальной гипертензии.
Ключевые слова: петлевые диуретики, артериальная гипертензия, торасемид, антигипертензивная терапия.
Key words: loop diuretics, essential hypertension, torasemide, antihypertensive therapy.
Ключевые слова: петлевые диуретики, артериальная гипертензия, торасемид, антигипертензивная терапия.
________________________________________________
Key words: loop diuretics, essential hypertension, torasemide, antihypertensive therapy.
Полный текст
Список литературы
1. Диагностика и лечение артериальной гипертензии. Системные гипертензии. Комитет экспертов РМОАГ/ВНОК. 2010; 3: 5–26.
2. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest 2007; 131: 1949–62.
3. Bennett NM, Shea S. Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100 cases. Am J Public Health 1988; 78: 636–40.
4. Колос И.П., Чазова И.Е., Терещенко С.Н., Наконечников С.Н. Риск сердечно-сосудистых осложнений у больных частыми гипертоническими кризами. Тер. арх. 2009; 9: 9–12.
5. Bhalla V, Hallows KR. Mechanisms of ENaC regulation and clinical implications. J Am Soc Nephrol 2008; 19: 1845–54.
6. Kalaitzidis R, Li S, Wang C et al. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009; 53 (Suppl. 4): 22–31.
7. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134 (8): 629–36.
8. Kostis JB, Shelton B, Gosselin G et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996; 131 (2): 350–5.
9. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547–59.
10. Russo D, Gazzotti RM, Testa A. Torasemide, a new loop diuretic, in patients with chronic renal failure. Nephron 1990; 55 (2): 141–5.
11. Fliser D, Schröter M, Neubeck M et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46 (2): 482–8.
12. Gehr TW, Rudy DW, Matzke GR et al. The pharmacokinetics of intravenous and oral torasemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56 (1): 31–8.
13. Risler T, Schwab A, Kramer B et al. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology 1994; 84 (Suppl. 2): 155–61.
14. Goodfriend TL, Ball DL, Oelkers W, Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): 45–50.
15. Struthers AD. Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 2002; 8: 18–22.
16. Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025–30.
17. López B, González A, Hermida N et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int Suppl 2008; 111: 19–23.
18. López B, González A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50 (9): 859–67.
19. Mosso L, Carvajal C, Gonzales A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–5.
20. Rossi GP, Bernini G, Caliumi C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48 (11): 2293–300.
21. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the insidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33–42.
22. Born-Frontsberg E, Reincke M, Rump LC et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009; 94 (4): 1125–30.
23. Berecek KH, Farag A, Bahtiyar G et al. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep 2004; 6 (3): 211–2.
24. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in patients with resistant hypertension. Hypertension 2007; 49: 839–45.
25. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000; 61 (1): 52–60.
26. Handler J. Maximizing diuretic therapy in resistant hypertension. J Clin Hypertens (Greenwich) 2007; 9 (10): 802–6.
2. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest 2007; 131: 1949–62.
3. Bennett NM, Shea S. Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100 cases. Am J Public Health 1988; 78: 636–40.
4. Колос И.П., Чазова И.Е., Терещенко С.Н., Наконечников С.Н. Риск сердечно-сосудистых осложнений у больных частыми гипертоническими кризами. Тер. арх. 2009; 9: 9–12.
5. Bhalla V, Hallows KR. Mechanisms of ENaC regulation and clinical implications. J Am Soc Nephrol 2008; 19: 1845–54.
6. Kalaitzidis R, Li S, Wang C et al. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009; 53 (Suppl. 4): 22–31.
7. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134 (8): 629–36.
8. Kostis JB, Shelton B, Gosselin G et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996; 131 (2): 350–5.
9. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547–59.
10. Russo D, Gazzotti RM, Testa A. Torasemide, a new loop diuretic, in patients with chronic renal failure. Nephron 1990; 55 (2): 141–5.
11. Fliser D, Schröter M, Neubeck M et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46 (2): 482–8.
12. Gehr TW, Rudy DW, Matzke GR et al. The pharmacokinetics of intravenous and oral torasemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56 (1): 31–8.
13. Risler T, Schwab A, Kramer B et al. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology 1994; 84 (Suppl. 2): 155–61.
14. Goodfriend TL, Ball DL, Oelkers W, Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): 45–50.
15. Struthers AD. Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 2002; 8: 18–22.
16. Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025–30.
17. López B, González A, Hermida N et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int Suppl 2008; 111: 19–23.
18. López B, González A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50 (9): 859–67.
19. Mosso L, Carvajal C, Gonzales A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–5.
20. Rossi GP, Bernini G, Caliumi C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48 (11): 2293–300.
21. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the insidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33–42.
22. Born-Frontsberg E, Reincke M, Rump LC et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009; 94 (4): 1125–30.
23. Berecek KH, Farag A, Bahtiyar G et al. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep 2004; 6 (3): 211–2.
24. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in patients with resistant hypertension. Hypertension 2007; 49: 839–45.
25. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000; 61 (1): 52–60.
26. Handler J. Maximizing diuretic therapy in resistant hypertension. J Clin Hypertens (Greenwich) 2007; 9 (10): 802–6.
Авторы
В.В.Фомин
ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ
fomin_vic@mail.ru
I.M.Sechenov First Moscow State Medical University, Ministry of Health and Social Development of Russia
fomin_vic@mail.ru
ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ
fomin_vic@mail.ru
________________________________________________
I.M.Sechenov First Moscow State Medical University, Ministry of Health and Social Development of Russia
fomin_vic@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.